Biodistribution of allogenic umbilical cord-derived mesenchymal stromal cells after fetal repair of myelomeningocele in an ovine model
Authors:
Open Access
- 15 July 2022
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 13 (1) , 1-6
Abstract
Background: Myelomeningocele (MMC) is a spinal cord congenital defect that leads to paraplegia, sphincter disorders and potential neurocognitive disabilities. Prenatal surgery of MMC provides a significant benefit compared to surgery at birth. Mesenchymal stromal cell (MSC) therapy as an adjuvant treatment for prenatal surgery showed promising results in animal experiments which could be considered for clinical use in human fetuses. Despite numerous reassuring studies on the safety of MSCs administration in humans, no study focused on MSCs biodistribution after a local MSCs graft on the fetal spinal cord. Aim: The purpose of our study was to assess the biodistribution of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) at birth in lambs who had a prenatal myelomeningocele repair using a fibrin patch seeded with allogenic UC-MSCs. Methods: After isolation, UC-MSCs were tagged using a green fluorescent protein (GFP)-containing lentiviral vector. MMC defects were surgically created at 75 days of gestation and repaired 15 days later using UC-MSCs patch. Lambs were delivered at 142 days and sacrificed. DNA extraction was performed among biopsies of the different organs and q-PCR analysis was used to detect the expression of GFP (GFP DNA coding sequence). Results: In our 6 surviving lambs grafted with UC-MSCs, GFP lentivirus genomic DNA was not detected in the organs. Conclusion: These reassuring data will support translational application in humans, especially since the first human clinical trial using mesenchymal stromal cells for in-utero treatment of MMC started recently in U.S.A.Keywords
This publication has 22 references indexed in Scilit:
- High density placental mesenchymal stromal cells provide neuronal preservation and improve motor function following in utero treatment of ovine myelomeningoceleJournal of Pediatric Surgery, 2019
- Significant Improvement of Acute Complete Spinal Cord Injury Patients Diagnosed by a Combined Criteria Implanted with NeuroRegen Scaffolds and Mesenchymal Stem CellsCell Transplantation, 2018
- Donor mesenchymal stem cell linetics after transamniotic stem cell therapy (TRASCET) for experimental spina bifidaJournal of Pediatric Surgery, 2018
- The Management of Myelomeningocele Study: full cohort 30-month pediatric outcomesAmerican Journal of Obstetrics and Gynecology, 2018
- Placental mesenchymal stromal cells seeded on clinical grade extracellular matrix improve ambulation in ovine myelomeningoceleJournal of Pediatric Surgery, 2018
- Placental Mesenchymal Stromal Cells Rescue Ambulation in Ovine MyelomeningoceleStem Cells Translational Medicine, 2015
- Different Culture Media Affect Proliferation, Surface Epitope Expression, and Differentiation of Ovine MSCStem Cells International, 2013
- Risk of tumorigenicity in mesenchymal stromal cell–based therapies—Bridging scientific observations and regulatory viewpointsCytotherapy, 2013
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical TrialsPLOS ONE, 2012
- A Randomized Trial of Prenatal versus Postnatal Repair of MyelomeningoceleNew England Journal of Medicine, 2011